Effect of eye ointmet lubratex in the prevetion ocular surface disorders (OSD)

Comparison of ocular lubratex and ocular vitamin A ointment in the prevention of ocular surface disorders (OSD) in Intensive Care Unit, A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017040733278N1

Enrollment

Registered

2017-07-25

Start date

2017-06-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Surface Disorders. Disorders of sclera, cornea, iris and ciliary body

Interventions

Intervention 1: Intervention group: After a standard eye care (eye wash and skin around it with normal saline) one of the eyes of patients is randomly selected. Then about two inches Lubratex Ointment

Prevention

Treatment - Drugs

Intervention group: After a standard eye care (eye wash and skin around it with normal saline) one of the eyes of patients is randomly selected. Then about two inches Lubratex Ointment every six hours

Control group: After a standard eye care (eye wash and skin around it with normal saline) other patient’s eye is selected. Then about two inches vitamin A Ointment every six hours, 5 days, is placed i

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age over 18 years; the healthy cornea in the initial examination; admitted to the intensive care unit for at least for 5 days; consciousness score according to the Glasgow Coma Scale less than 10; lack of trauma to the face or eyes; no history of eye problems. Exclusion criteria: having chemosis; differences of scores in the preliminary examination of the eyelid position; Bell's palsy or unilateral hemiplegia; allergy to Lubratex; closed suction method; if the patient is able to blink; corneal disorder at any stage of the testing.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ocular Surface Disorders. Timepoint: Before intervention- 5 days after the intervention. Method of measurement: Assessment tools for ocular surface disorders in this study including the Schirmer's and fluorescin tests. Schirmer's test once before and once when the study is completed will be done. To perform this test graded Schirmer's paper is placed in choledosac at the junction of the middle third and outer third of the eyelid and the lid is closed. After five minutes, wet bar's height is measured in millimeters. Fluorescein test once at the beginning and once on the fifth day is done.	—

Measure

Time frame

Ocular Surface Disorders. Timepoint: Before intervention- 5 days after the intervention. Method of measurement: Assessment tools for ocular surface disorders in this study including the Schirmer's and fluorescin tests. Schirmer's test once before and once when the study is completed will be done. To perform this test graded Schirmer's paper is placed in choledosac at the junction of the middle third and outer third of the eyelid and the lid is closed. After five minutes, wet bar's height is measured in millimeters. Fluorescein test once at the beginning and once on the fifth day is done.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMitra Badparva

Shahroud University of Medical Sciences

badparva@shmu.ac.ir+98 23 3239 5054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026